Riley M Whalen

Riley M Whalen

Division of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Thomas Lee SuttonThomas Lee Sutton
Thomas Lee Sutton
RPResident Kamalesh Patel
Resident Kamalesh Patel
AAAshley Anderson
Ashley Anderson
SBStephen G. Bowden
Stephen G. Bowden
Riley M WhalenRiley M Whalen
Riley M Whalen
MWMelissa H. Wong
Melissa H. Wong
Cancer remains a significant cause of mortality in developed countries, due in part to difficulties in early detection, understanding disease biology, and assessing treatment response. If effectively harnessed, circulating biomarkers promise to fulfill these needs through non-invasive “liquid” biopsy. While tumors disseminate genetic material and cellular debris into circulation, identifying clinically relevant information from these analytes has proven difficult. In contrast, cell-based circulating biomarkers have multiple advantages, including a source for tumor DNA and protein, and as a cellular reflection of the evolving tumor. While circulating tumor cells (CTCs) have dominated the circulating cell biomarker field, their clinical utility beyond that of prognostication has remained elusive, due to their rarity. Recently, two novel populations of circulating tumor-immune hybrid cells in cancer have been characterized: cancer-associated macrophage-like cells (CAMLs) and circulating hybrid cells (CHCs). CAMLs are macrophage-like cells containing phagocytosed tumor material, while CHCs can result from cell fusion between cancer and immune cells and play a role in the metastatic cascade. Both are detected in higher numbers than CTCs in peripheral blood and demonstrate utility in prognostication and assessing treatment response. Additionally, both cell populations are heterogeneous in their genetic, transcriptomic, and proteomic signatures, and thus have the potential to inform on heterogeneity within tumors. Herein, we review the advances in this exciting field.

11 November 2019 in eLife
Verified
Journal Article
Open access
MCMatthew M Crane
Matthew M Crane
ARAdam E Russell
Adam E Russell
BSBrent J Schafer
Brent J Schafer
BBBen W Blue
Ben W Blue
Riley M WhalenRiley M Whalen
Riley M Whalen
MKMatt Kaeberlein
Matt Kaeberlein
Genome instability is a hallmark of aging and contributes to age-related disorders such as cancer and Alzheimer’s disease. The accumulation of DNA damage during aging has been linked to altered cell cycle dynamics and the failure of cell cycle checkpoints. Here, we use single cell imaging to study the consequences of increased genomic instability during aging in budding yeast and identify striking age-associated genome missegregation events. This breakdown in mitotic fidelity results from the age-related activation of the DNA damage checkpoint and the resulting degradation of histone proteins. Disrupting the ability of cells to degrade histones in response to DNA damage increases replicative lifespan and reduces genomic missegregations. We present several lines of evidence supporting a model of antagonistic pleiotropy in the DNA damage response where histone degradation, and limited histone transcription are beneficial to respond rapidly to damage but reduce lifespan and genomic stability in the long term.

23 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MPMichael Parappilly
Michael Parappilly
YCYuki Chin
Yuki Chin
Riley M WhalenRiley M Whalen
Riley M Whalen
AAAshley Anderson
Ashley Anderson
TRTrinity Robinson
Trinity Robinson
ASAlison HALL Skalet
Alison HALL Skalet
Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologic outcomes compared to circulating tumor cells (CTCs). We sought to investigate the potential of CHCs as a prognostic biomarker in uveal melanoma. Methods: We isolated peripheral blood monocular cells from uveal melanoma patients at the time of primary treatment and used antibodies against leukocyte and melanoma markers to identify and enumerate CHCs and CTCs by immunocytochemistry. Results: Using a multi-marker approach to capture the heterogeneous disseminated tumor cell population, detection of CHCs was highly sensitive in uveal melanoma patients regardless of disease stage. CHCs were detected in 100% of stage I-III uveal melanoma patients (entire cohort, n = 68), whereas CTCs were detected in 58.8% of patients. CHCs were detected at levels statically higher than CTCs across all stages (p = 0.05). Moreover, CHC levels, but not CTCs, predicted 3 year progression-free survival (p < 0.03) and overall survival (p < 0.04). Conclusion: CHCs are a novel and promising prognostic biomarker in uveal melanoma.

28 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Riley M WhalenRiley M Whalen
Riley M Whalen
AAAshley N. Anderson
Ashley N. Anderson
JJJocelyn A. Jones
Jocelyn A. Jones
ZSZachary Sims
Zachary Sims
YCYoung Hwan Chang
Young Hwan Chang
SGSummer L Gibbs
Summer L Gibbs
Persistently high, worldwide mortality from cancer highlights the unresolved challenges of disease surveillance and detection that impact survival. Development of a non-invasive, blood-based biomarker would transform survival from cancer. We demonstrate the functionality of ultra-high content analyses of a newly identified population of tumor cells that are hybrids between neoplastic and immune cells in patient matched tumor and peripheral blood specimens. Using oligonucleotide conjugated antibodies (Ab-oligo) permitting cyclic immunofluorescence (cyCIF), we present analyses of phenotypes among tumor and peripheral blood hybrid cells. Interestingly, the majority of circulating hybrid cell (CHC) subpopulations were not identified in tumor-associated hybrids. These results highlight the efficacy of ultra-high content phenotypic analyses using Ab-oligo based cyCIF applied to both tumor and peripheral blood specimens. The combination of a multiplex phenotypic profiling platform that is gentle enough to analyze blood to detect and evaluate disseminated tumor cells represents a novel approach to exploring novel tumor biology and potential utility for developing the population as a blood-based biomarker in cancer.

1 January 2019 in Translational Medicine of Aging
Verified
Journal Article
Open access
MCMatthew M. Crane
Matthew M. Crane
MTMitsuhiro Tsuchiya
Mitsuhiro Tsuchiya
BBBen W. Blue
Ben W. Blue
JAJared D. Almazan
Jared D. Almazan
KCKenneth L. Chen
Kenneth L. Chen
MKMatt Kaeberlein
Matt Kaeberlein
An increase in cell size with age is a characteristic feature of replicative aging in budding yeast. Deletion of the gene encoding Whi5 results in shortened duration of G1 and reduced cell size, and has been previously suggested to increase replicative lifespan. Upon careful analysis of multiple independently derived haploid and homozygous diploid whi5Δ mutants, we find no effect on lifespan, but we do confirm the reduction in cell size. We suggest that instead of antagonizing lifespan, the elongated G1 phase of the cell cycle during aging may actually play an important role in allowing aged cells time to repair accumulating DNA damage.

24 November 2023
Verified
Book Chapter
Closed access
PDF file
RPRanish K. Patel
Ranish K. Patel
MPMichael Parappilly
Michael Parappilly
SRShahrose Rahman
Shahrose Rahman
ISIssac R. Schwantes
Issac R. Schwantes
MSMarisa Sewell
Marisa Sewell
MWMelissa H. Wong
Melissa H. Wong